Julie Chang is a Hematology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9242 Bear Claw Way
Madison, WI 537172734
Telephone
608-827-9665Provider last certified this registry record 21 Oct 2025.
Clinical trials
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Sponsor: University of Wisconsin, Madison
- Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Incyte CorporationProgram year20251 payment
- ADC THERAPEUTICS AMERICA, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
33.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33.8%Acyclovir100%Part D≥60 patientsMetabolism & gastrointestinal
21.1%Proton pump inhibitor5.7%Omeprazole78%Pantoprazole Sodium22%Part D<11 patientsH2 blocker5.2%Famotidine100%Part D≥20 patients+ 3 more classes in this area
Cancer & immunology
18.5%Kinase inhibitor13.8%Brukinsa48%Calquence19%Jaypirca19%Imbruvica14%Part D<11 patientsBCL-2 Inhibitor4.7%Venclexta100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”